CD40 Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, CD40 pipeline constitutes key companies continuously working towards developing CD40 treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"CD40 Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CD40 Market.

The CD40 Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the CD40 Pipeline Report: https://www.delveinsight.com/sample-request/cd40-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel CD40 treatment therapies with a considerable amount of success over the years.
• CD40 companies working in the treatment market are Boston Immune Technologies and Therapeutics, Harbour BioMed, Bristol-Myers Squibb, Lyvgen Biopharma, Shattuck Labs, Inc, Novartis, Eledon Pharmaceuticals, Eucure Biopharma, and others, are developing therapies for the CD40 treatment
• Emerging CD40 therapies in the different phases of clinical trials are- BITD401412, HBM9027, BMS 986325, LVGN7409, SL-172154, CFZ-533, AT-1501, YH003, and others are expected to have a significant impact on the CD40 market in the coming years.
• In August 2025, An experimental cancer therapy has shown promising results in a small clinical trial, effectively targeting aggressive breast and skin cancers. The treatment, an enhanced CD40 agonist administered via direct tumor injection, was tested in 12 human participants. Of these, six patients experienced tumor shrinkage, and two participants achieved complete remission, highlighting the potential of this novel approach in cancer treatment.
• In October 2022, Eucure Biopharma has established a collaboration with ISU ABXIS Co., a clinical-stage company in Korea specializing in immuno-oncology drug development. According to the agreement, ISU ABXIS will employ the sequence of YH003, a humanized agonistic anti-CD40 antibody from Biocytogen currently undergoing phase II clinical trials. The objective is to create several sets of tri-specific antibodies using ISU ABXIS's technology platform and advance the development of cancer drugs for various indications.

CD40 Overview
CD40, or Cluster of Differentiation 40, is a cell surface receptor protein that plays a crucial role in the immune system. It is primarily found on the surface of immune cells, including B cells, dendritic cells, and macrophages. CD40 is a member of the tumor necrosis factor (TNF) receptor superfamily.

Get a Free Sample PDF Report to know more about CD40 Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/cd40-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging CD40 Drugs Under Different Phases of Clinical Development Include:
• BITD401412: Boston Immune Technologies and Therapeutics
• HBM9027: Harbour BioMed
• BMS 986325: Bristol-Myers Squibb
• LVGN7409: Lyvgen Biopharma
• SL-172154: Shattuck Labs, Inc
• CFZ-533: Novartis
• AT-1501: Eledon Pharmaceuticals
• YH003: Eucure Biopharma

CD40 Pipeline Therapeutics Assessment
• CD40 Assessment by Product Type
• CD40 By Stage and Product Type
• CD40 Assessment by Route of Administration
• CD40 By Stage and Route of Administration
• CD40 Assessment by Molecule Type
• CD40 by Stage and Molecule Type

DelveInsight's CD40 Report covers around products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further CD40 product details are provided in the report. Download the CD40 pipeline report to learn more about the emerging CD40 therapies at:
https://www.delveinsight.com/sample-request/cd40-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the CD40 Therapeutics Market include:
Key companies developing therapies for CD40 are - Juno Therapeutics Inc., ImmuNext, Inc., MedImmune, LLC, XL-protein GmbH, Biogen, Inc., Targovax AS, Bristol-Myers Squibb Company, eTheRNA Immunotherapies NV, and others.

CD40 Pipeline Analysis:
The CD40 pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of CD40 with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CD40 Treatment.
• CD40 key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• CD40 Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CD40 market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about CD40 drugs and therapies-
https://www.delveinsight.com/sample-request/cd40-agonist-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

CD40 Pipeline Market Drivers
• Increasing prevalence of cancer and autoimmune disorders worldwide, rise in the research and development activities are some of the important factors that are fueling the CD40 Market.

CD40 Pipeline Market Barriers
• However, lack of in-depth understanding of the signaling pathway and other factors are creating obstacles in the CD40 Market growth.

Scope of CD40 Pipeline Drug Insight
• Coverage: Global
• Key CD40 Companies: Boston Immune Technologies and Therapeutics, Harbour BioMed, Bristol-Myers Squibb, Lyvgen Biopharma, Shattuck Labs, Inc, Novartis, Eledon Pharmaceuticals, Eucure Biopharma, and others
• Key CD40 Therapies: BITD401412, HBM9027, BMS 986325, LVGN7409, SL-172154, CFZ-533, AT-1501, YH003, and others
• CD40 Therapeutic Assessment: CD40 current marketed and CD40 emerging therapies
• CD40 Market Dynamics: CD40 market drivers and CD40 market barriers

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.